MIAMI, Feb. 16, 2017 (GLOBE NEWSWIRE) -- The Female Health Company / Veru Healthcare (NASDAQ:FHCO) today announced the appointment of Matthew C. Gosnell, Ph.D., as Senior Vice President of Manufacturing, Preclinical and Pharmaceutical Development, effective February 15, 2017.
Gosnell has a Ph.D. in analytical chemistry and more than 20 years of experience in pharmaceutical manufacturing, development and sourcing. His experience ranges from preclinical and investigational new drugs (INDs) through 505(b)(2) and 505(b)(1) New Drug Applications (NDAs) and commercialization. He will be responsible for identifying clinical and commercial manufacturing partners, chemical synthesis and process scale up development, development and clinical trial materials manufacturing and processes, documentation and submissions related to chemistry, manufacturing and control.
“An accomplished scientist and drug developer, Dr. Gosnell brings hands-on experience in strategic planning and execution of process development and manufacturing of both early and late stage drug products,” said Mitchell Steiner, M.D., President and Chief Executive Officer of The Female Health Company / Veru Healthcare. “He has extensive knowledge and expertise in leading multiple projects in various stages of development and identifying and managing new drug manufacturing sites for clinical development and commercial supply. Over his career, Dr. Gosnell has made significant contributions to several 505(b)(2) and 505(b)(1) NDAs including Celebrex®, Risperdal® Consta® and Vivitrol® and served in senior level positions with GTx, Alkermes, Pharmacia, McNeil Specialty Products (a division of Johnson & Johnson) and Miles (a unit of Bayer AG).”
Prior to joining the Company, Dr. Gosnell served as Senior Director, Product Development and Analytical Sciences for GTx, Inc., where he advanced multiple drug candidates into successive clinical stages of development. Earlier in his career, he was Director, Quality Technical Services (Analytical Development and Stability) for Alkermes, Inc., Analytical Team Leader for Pharmacia Research and Development and Senior Scientist at McNeil Specialty Products Company. Dr. Gosnell began his career as Scientist with Miles, Inc., after earning a Doctoral degree in Analytical Chemistry from Oklahoma State University and a Bachelor of Science degree in Chemistry and Mathematics-Computer Science from Manchester College.
About The Female Health Company / Veru Healthcare
The Female Health Company / Veru Healthcare is a pharmaceutical and medical device company, with a focus on the development and commercialization of pharmaceuticals that qualify for the FDA's 505(b)(2) accelerated regulatory approval pathway as well as the 505(b)(1) pathway. The Company does business both as "Veru Healthcare" and as "The Female Health Company" and is organized as follows:
- Veru Healthcare manages the Pharmaceuticals Division, which develops and commercializes pharmaceutical products for men's and women's health and oncology.
- Veru Healthcare manages the Consumer Health / Medical Devices Division, which is focused on commercializing sexual healthcare products and devices for the consumer market, including the Company's FC2 Female Condom® in the consumer health products sector and PREBOOST® medicated individual wipe, which is a male genital desensitizing drug product that helps in the prevention of premature ejaculation.
- The Female Health Company manages the Global Public Health Division, which is focused on the global public health sector FC2 business. This division markets the Company’s Female Condom (FC2) to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world.
More information about the Female Health Company and its products can be found at www.femalehealth.com, www.veruhealthcare.com and www.femalecondom.org. For corporate and investor-related information about the Company, please visit www.FHCinvestor.com.